

1 A 10-year retrospective analysis of *Toxoplasma gondii* qPCR screening in allogeneic hematopoietic
2 stem cell transplantation recipients

3

4 Alienor Xhaard¹, Alban Villate², Samia Hamane³, David Michonneau^{1,4,7}, Jean Menotti⁵, Marie Robin¹,
5 Flore Sicre de Fontbrune¹, Nathalie Dhédin⁶, Régis Peffault de la Tour^{1,7}, Gérard Socié^{1,4,7*}, and
6 Stéphane Bretagne^{3,7*}

7

8 1 Service d'hématologie-greffe, Hôpital Saint-Louis, APHP, Université Paris Diderot, Paris, France

9 2 Service d'hématologie et thérapie cellulaire, CHRU Tours, Tours, France

10 3 Laboratoire de mycologie-parasitologie, Hôpital Saint-Louis, APHP, Université Paris Diderot, Paris,
11 France

12 4 INSERM UMR 976 (Team Insights), Université Paris Diderot, Paris, France

13 5 Laboratoire de mycologie-parasitologie, Hospices Civils de Lyon, Lyon, France

14 6 Service d'hématologie adolescents jeunes adultes, Hôpital Saint-Louis, APHP, Université Paris
15 Diderot, Paris, France

16 7 Université Paris Cité

17 * These authors contributed equally to this work

18

19

20 **Running title:** *Toxoplasma gondii* qPCR in alloHSCT recipients

21

22

23 Abstract: 200 words

24 Article: 2 999 words

25 Tables: 2

26 Figures: 4

27 Supplementary table: 1

28 References: 31

- 1 Corresponding author:
- 2 Dr. Aliénor Xhaard
- 3 Service d'hématologie-greffe, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Université
- 4 Paris-Diderot
- 5 1 avenue Claude Vellefaux, 75475 Paris, Cedex 10, France.
- 6 Phone: +33 1 42 49 96 39
- 7 Fax: +33 1 42 49 96 36
- 8 E-mail: alienor.xhaard@aphp.fr
- 9 ORCID: 0000-0002-4449-989X
- 10

1 **Abstract**

2 Weekly blood *Toxoplasma gondii* DNA screening using real-time quantitative polymerase chain
3 reaction (qPCR) has been implemented in all allogeneic hematopoietic stem cell transplantation
4 (alloHSCT) recipients at our hospital. We retrospectively analyzed the consequences of a positive blood
5 qPCR in the management of *Toxoplasma* infection (TI) and disease (TD).

6 From 2011 to 2020, 52 (4.13%) of 1 257 alloHSCT recipients had at least one positive qPCR, 45 (3.5%)
7 with TI and seven (0.56%) with TD (central nervous system involvement). Forty-four patients were
8 qPCR-positive before day 100, 30 without and 14 with anti-*Toxoplasma* prophylaxis. Twenty-five of
9 them (56.8%) started or continued prophylactic dosage treatment: all became qPCR-negative, including
10 20 (80%) receiving only prophylactic dosage treatment. Twenty-four of them (54.5%) received non-
11 prophylactic dosage treatment: qPCR became negative in 22/24 (91.7%), while TI contributed to death
12 in two cases. Six of the eight patients diagnosed after D100 were breakthrough TI or TD. No death was
13 attributable to TI or TD. *qPCR* kinetics available for 24 patients increased until anti-*Toxoplasma*
14 treatment began, then decreased with all treatment regimens.

15 Clinical follow-up and qPCR monitoring with quantification of the parasitic load appears a reasonable
16 strategy to avoid TD and to use minimal effective dosage of anti-*Toxoplasma* treatments.

17

18

1 **Introduction**

2 Toxoplasmosis is a zoonosis caused by *Toxoplasma gondii*, an intracellular coccidian parasite with
3 numerous warm-blood intermediate hosts, and cats as the definite host. In humans, primary infection
4 occurs after ingestion of cysts-containing undercooked meat or oocysts from the environment. Primary
5 infection, usually asymptomatic, leads to the latency of bradyzoites in astrocytes, retina cells and
6 muscles. In immunocompromised patients, toxoplasmosis mainly results from reactivation of latent
7 cysts and its incidence depends on geographical endemicity, highly dependent on culinary habits.

8 Toxoplasmosis in allogeneic hematopoietic stem cell transplantation (alloHSCT) recipients remains a
9 matter of concern (1). Prophylaxis using trimethoprim/sulfamethoxazole (TMP/SMX) is recommended
10 in seropositive patients (2,3), but usually postponed until engraftment, for fear of possible hematological
11 toxicity. Most cases occur between day 20 (D20) and D180 post-alloHSCT (4–6), but later or sooner
12 occurrences have been reported (7). Outcomes were particularly dismal before the 2000s, with an
13 estimated attributable mortality rate over 50%, probably due to a late diagnosis (8–10). Early
14 *Toxoplasma* detection, using real-time quantitative polymerase chain reaction (qPCR) monitoring, has
15 enabled the incidence of *Toxoplasma* disease and subsequent mortality to decrease. Indeed, circulating
16 DNA detection usually precedes symptoms by 14–16 days (4,6,11). However, qPCR screening leads to
17 the observation of qPCR-positive poorly symptomatic or asymptomatic patients: clinicians can then be
18 reluctant to prescribe drugs possibly responsible for hematological toxicity (TMP/SMX or other
19 sulfonamides) (12). Moreover, it is not yet known if all qPCR-positive patients will develop *Toxoplasma*
20 disease in the absence of specific treatment, and there are no data and no recommendations on the best
21 therapeutic option for asymptomatic patients with positive qPCR.

22 In our center, a strategy of weekly *Toxoplasma* qPCR screening of all alloHSCT recipients has been
23 implemented for more than 10 years. The aims of this observational monocentric retrospective study
24 were to describe the epidemiology of toxoplasmosis in alloHSCT recipients, and anti-*Toxoplasma*
25 treatment in qPCR-positive patients.

26

27 **Patients and methods**

28 *Patients and definitions*

1 The study was conducted in the JACIE- (Joint Accreditation Committee for International Society for
2 Cell and Gene Therapy (ISCT) Europe) and EBMT- (European Society for Blood and Marrow
3 Transplantation) accredited hematology transplantation ward at Saint-Louis Hospital (Paris, France).
4 AlloHSCT recipients transplanted between January 2011 and December 2020 were included. Data were
5 collected from the PROMISE database and local medical records.

6 *Toxoplasma* infection (TI) and disease (TD) were defined according to the European Society for Blood
7 and Marrow Transplant-Infectious Diseases Working Party guidelines (4,13). TI was defined as \geq one
8 positive PCR test from blood in a patient without evidence of organ involvement, with or without fever.
9 TD was defined as definite (histological evidence), probable (clinical and radiological evidence plus \geq
10 one positive PCR test from blood, cerebrospinal fluid (CSF) or bronchoalveolar lavage fluid (BAL), and
11 absence of other pathogen), or possible (suggestive imaging and response to specific treatment, but no
12 laboratory evidence). The day of the first positive qPCR was defined as the day of TI or TD diagnosis.
13 Mortality was considered toxoplasmosis-attributable if it occurred with positive qPCR or compatible
14 clinical signs, and in the absence of alternative diagnosis. Toxoplasmosis was considered as a death-
15 contributing factor if qPCR remained positive while the patient died for another identified cause (13).

16

17 *Microbiological and diagnostic investigations*

18 Prior to alloHSCT, an anti-*Toxoplasma* immunoglobulin-G (IgG) assay was systematically performed
19 (Platelia Toxo IgG TMB BIORAD until 2014 and ARCHITECT Toxo IgG thereafter) in donors and
20 recipients (recipient within three months and donor within 28 days, respectively). The in-house qPCR
21 targeted the *Toxoplasma*-specific AF 146527 DNA sequence (14) with an internal control (Simplexa™
22 Extraction & Amplification Control, Focus Diagnostics). qPCR monitoring was performed weekly on
23 venous blood samples (1 ml), regardless of serological status from alloHSCT until D100, and thereafter
24 at the discretion of the physician in cases of graft-versus-host-disease (GVHD), prolonged
25 immunosuppression, or hospitalization (2,15). qPCR results were expressed as a quantification cycle
26 (Cq) (16), with a low parasitic load corresponding to Cqs between 36 and 45. The laboratory subscribed
27 to an independent external quality control for both *Toxoplasma* serology (Centre Toulousain pour le

1 contrôle de qualité en Biologie clinique, France) and qPCR (Quality Control for Molecular Diagnostics,
2 Glasgow, Scotland, United Kingdom).

3 In cases of positive *Toxoplasma* qPCR, the decision over whether to perform a diagnostic work-up was
4 made by the physician in charge and usually included a central nervous system (CNS) computed-
5 tomography (CT-scan) or magnetic-resonance imaging, thorax and abdomen CT-scans and fundus
6 ophthalmoscopy. Blood control qPCR was performed once to twice weekly after the first positive
7 sample.

8

9 *Anti-Toxoplasma prophylaxes and treatment (Table 1)*

10 *Toxoplasma gondii* and *Pneumocystis jirovecii* prophylaxis was given to all patients after engraftment.
11 Prophylaxis in our center was pyrimethamine/sulfadoxine (P/So) until commercialization ceased in 2017
12 (15,17). From then on, the most used prophylaxis has been TMP/SMX. However, atovaquone was
13 preferentially used in patients with cytopenia, due to concerns about the possible hematological toxicity
14 of TMP/SMX (12). The therapeutic option was led by the treating physician. Since qPCR was performed
15 as a screening test before D100 and according to clinical suspicion later, we separated the two situations
16 for further analyses.

17

18 *Ethical consideration*

19 The Institutional Review Board approved this study of the Saint-Louis Hospital. All patients gave their
20 written consent for data collection. The study followed the Declaration of Helsinki.

21

22 *Statistical analyses*

23 Continuous variables are expressed as median [IQR] and compared using Dunn's test with Bonferroni
24 correction. Categorical variables are expressed as frequencies (percentages) and compared using
25 Fisher's test. All analyses were performed using SAS version 9.4.6 (SAS Institute Inc., Cary, NC, USA).
26 A two-tailed significance level $p < 0.05$ was used.

27

28 **Results**

1 *Study population and toxoplasmosis incidence*

2 During the 10-year study period, 1 258 alloHSCTs were performed, including 1 257 donor/recipient
3 (D/R) couples with available pre-alloHSCT *Toxoplasma gondii* serology. Anti-*Toxoplasma* IgG were
4 positive in 734 recipients (58.3%) and 379 donors (30.1%). Excluding 65 cord blood alloHSCTs, anti-
5 *Toxoplasma* IgG were positive in 264/579 (45.6%) of related and in 114/613 (18.6%) of unrelated adult
6 donors. The D/R combinations were 272 (21.6%) D+/R+, 462 (36.8%) D-/R+, 107 (8.5%) D+/R-, and
7 416 (33.1%) D-/R-. The median age of the 1 257 patients was 45.6 years [IQR: 28-58]: 31 [IQR: 21-46]
8 for *T. gondii* seronegative patients and 53 [IQR: 40-55] for seropositive patients. Overall mortality at
9 D100 and one year after alloHSCT were 135/1 257 (10.7%) and 309/1 257 (24.6%) for the entire cohort,
10 and 127/1 205 (10.5%) and 291/1 205 (24.1%) for the qPCR-negative patients, respectively.

11 During the study period, 22 154 qPCR tests were performed (median/patient: 15 [IQR: 9-21]) without
12 significant variation according to the year of sampling. In total, 52 patients (4.13%) had at least one
13 *T. gondii* positive qPCR, i.e. a mean of five cases a year.

14

15 *Characteristics of the 52 T. gondii positive qPCR patients (Table 2 and supplementary Table 1)*

16 Thirty-one patients were male (56.9%), and median age at alloHSCT was 42 [IQR: 16-52]. Before
17 alloHSCT, five patients were anti-*Toxoplasma* IgG negative. Two seropositive patients had a previous
18 *Toxoplasma* reactivation before alloHSCT (one qPCR-positive during a septic shock treated by
19 TMP/SMX and one ocular toxoplasmosis treated by atovaquone, seven and three months before
20 alloHSCT, respectively). Forty-five patients had TI and seven had CNS TD (3.5% and 0.56% of 1 257
21 alloHSCT recipients, respectively). The seven TD were probable (CSF qPCR was positive in the two
22 lumbar punctures performed) and the positive blood qPCR anticipated the diagnosis of cerebral
23 involvement in all cases. Twenty-two (42.3%) patients died a median of 155 days (IQR [77-253]) after
24 alloHSCT: toxoplasmosis contributed to death in two TI and one TD, respectively. In patients diagnosed
25 before D100, the overall mortality rate was 43% (19/44), and 64% (9/14) in patients with anti-
26 *Toxoplasma* prophylaxis.

27 Forty-four out of 52 patients (84.6%) were qPCR-positive before D100, 30/44 (68.2%) without anti-
28 *Toxoplasma* prophylaxis (28 TI, 2 TD) and 14/44 (31.8%) with prophylaxis (12 TI, 2 TD). The first

1 qPCR-positive result was observed sooner after alloHSCT in patients without prophylaxis than with
2 prophylaxis (median: 19 days [IQR: 14-25] vs. 48 days [IQR: 28-61], $p= 0.0003$). The median number
3 of positive qPCR and the median time from first-positive to first-negative qPCR were not significantly
4 different between patients with or without prophylaxis.

5 Eight out of 52 patients (15.4%) were qPCR-positive after D100, while receiving steroids for GVHD
6 ($n= 7$) or chemotherapy for post-transplant acute lymphoblastic leukemia relapse ($n= 1$). In six cases out
7 of eight (75%), qPCR was performed as part of a systematic screening for outpatients ($n= 3$) or inpatients
8 (hospitalized for GVHD in two cases and sepsis in one case). In the other two out of eight cases (25%),
9 qPCR was performed for neurological symptoms. In total after D100, five patients (63%) had TI and
10 three (37%) had TD.

11

12 *Analysis of qPCR results according to treatment*

13 *Diagnosis before D100 (Figure 1).*

14 Out of the 44 patients diagnosed before D100, 30 patients had no prophylaxis. Two of them (7%) became
15 spontaneously qPCR-negative on a second evaluation, but were nevertheless subsequently started on
16 prophylactic treatment and qPCR remained negative. For the other 28 patients, a second qPCR showed
17 an increased parasitic load. Fifteen out of 28 patients (53.6%) received pre-emptive treatment at
18 prophylactic dosage: all patients eventually became PCR-negative, including five after a change to non-
19 prophylactic dosage treatment. Treatment was well tolerated without toxicity-related withdrawal.
20 Thirteen out of 28 patients (46.4%) received pre-emptive treatment at non-prophylactic dosage: two
21 patients with TI died of GVHD with persistently positive *Toxoplasma* qPCR, while 11 patients (nine TI
22 and two CNS TD) became qPCR-negative (including one after change from intermediate to high dosage
23 treatment). Treatment was changed for toxicity in three cases and suspicion of P/Sa malabsorption in
24 one case. The detailed prescriptions and outcomes are reported in **Figure 1**.

25 For the 14 qPCR-positive patients while receiving anti-*Toxoplasma* prophylaxis (**Figure 2**), the first
26 qPCR was positive a median of 18 days [IQR: 8-34] after prophylaxis started. Prophylaxis was not
27 modified in 8/14 (57%) TI patients, and all became PCR-negative. Prophylaxis was changed to pre-
28 emptive non-prophylactic treatment in 6/14 (43%) cases, including two CNS TD. All patients eventually

1 became qPCR-negative and both cases with CNS TD resolved (including one after a change of high-
2 dosage treatment). Treatment was changed for toxicity in one case.

3 In total, all 25/44 patients (56.8%) who started or continued prophylactic dosage treatment became
4 qPCR-negative: 20/25 (80%) received only prophylactic dosage treatment, and 5/25 (20%) needed
5 treatment increase to non-prophylactic dosage. In total, 24/44 patients (54.5%) received non-
6 prophylactic dosage treatment: qPCR became negative in 22/24 cases (91.7%), while TI contributed to
7 death in two cases. No death was attributable to TI or TD.

8

9 *Diagnosis after D100 (n=8)*

10 *Toxoplasma gondii* qPCR was positive after D100 in eight patients (**Figure 3**). One patient with TI and
11 one with TD without prophylaxis received pyrimethamine/sulfadiazine (P/Sa) at non-prophylactic
12 dosage. Both patients died, and CNS TD contributed to death in one case. Breakthrough TI (n=4) or TD
13 (n=2) occurred in six patients while receiving P/So (n= 1) or prophylactic TMP/SMX (n= 5). Three
14 patients remained on prophylaxis and all became qPCR-negative. Three patients were changed from
15 prophylaxis to pre-emptive treatment at non-prophylactic dosage, and all became qPCR-negative.
16 Treatment was changed for toxicity in four cases.

17

18 *DNA load kinetic (Figure 4)*

19 We were able to analyze the parasitic load of 24 patients with a qPCR result available either on the day
20 of treatment implementation or the previous day, and a qPCR result within seven days before and after
21 treatment began. Before treatment, the median decrease of the Cq values was 1 Cq/day [0.5-1.5] (i.e., a
22 median increase of 4.0 [1.1-30.3] parasites/ml of blood/day). After treatment, assuming that the
23 regression was linear between two points, the median increase was 1.2 Cq/day [0.4-2.3] (i.e., a median
24 decrease of 2.8 [1.1-13.8] parasites/ml of blood/day (after calculation performed as in (14)). The results
25 are presented in **Figure 4** according to the anti-*Toxoplasma* treatment and dosage, without a significant
26 difference on the kinetics.

27

28 **Discussion**

1 Despite the high prevalence of anti-*Toxoplasma* IgG positivity (58.3% of alloHSCT recipients),
2 toxoplasmosis was infrequent in our 10 year-long study, with 0.56% and 3.5% of our patients diagnosed
3 with TI and TD, respectively. The overall prevalence of 4.13% is close to the prevalence reported in the
4 most recent studies (3.9-4.1%) (7,18,19), whereas older studies reported higher figures, from 8.7 to
5 18.6% (4,6,20–22). This decrease can be ascribed to the decreasing seroprevalence in the general
6 population, due to changes in lifestyle and food consumption (23). Other potential sources of differences
7 include the seropositivity prevalence in the considered country (24), the screened population (only
8 seropositive or all alloHSCT recipients (19)), the PCR assay used (the AF146527 DNA sequence being
9 more sensitive than the B1 gene (25)), the number of positive PCR results considered for diagnosis (≥ 2
10 in (18), versus ≥ 1 in others), and the frequency of sampling (usually once weekly). Finally, it can also
11 be simply ascribed to a better acceptance of TMP/SMX as prophylaxis of both toxoplasmosis and
12 pneumocystosis (21).

13 In our cohort, the first positive qPCR during systematic screening was mainly observed (30/44= 68.2%)
14 before prophylaxis started, as previously reported (7,19,21). A second qPCR with an increased parasitic
15 load definitively advocated for an ongoing multiplication of the parasite, and therefore prompt pre-
16 emptive treatment. Moreover, the decrease of the parasitic load following treatment implementation was
17 indicative of drug effectiveness (26). Therefore, the qPCR screening is of utmost importance before
18 prophylaxis is begun, or when the center policy is to avoid TMP/SMX (18).

19 We confirm that systematic qPCR screening is associated with a better prognosis of toxoplasmosis (6),
20 as no death was directly attributable to toxoplasmosis in our cohort. However, the prognosis of our
21 patients was still dismal, with an overall mortality rate of 43% in patients diagnosed before D100. This
22 conclusion differs from that of Conrad et al., who reported a toxoplasmosis-attributable mortality of
23 43.5% (19). In our cohort, the decrease of the parasitic load definitively shows that the anti-*Toxoplasma*
24 treatment was effective in controlling the parasite growth, acknowledging this is not sufficient to avoid
25 death (GVHD was the main cause of death in our cohort, as already described (27)).

26 We report the occurrence of breakthrough TI and TD in 20 patients receiving prophylaxis (including
27 TMP/SMX in 11 and five cases before and after D100, respectively), although it is hard to evaluate
28 observance for cases occurring late after alloHSCT. Hypotheses are that the usual prophylaxis dosage

1 is suboptimal to control the parasite, or that gut GVHD alters prophylactic treatment absorption. One
2 can also wonder if the qPCR-positivity in these cases can be considered as a marker of global frailty and
3 immunosuppression, placing these patients into a population at high risk of death.

4 If one can reach a consensus on the use of qPCR for screening alloHSCT recipients, there are no definite
5 recommendations concerning drugs and dosage. Firstly, some patients can become spontaneously
6 qPCR-negative. This can be expected in cases of a parasitic load at the limit of detection of the qPCR
7 and one can wait for a second positive result before starting anti-*Toxoplasma* treatment, as proposed by
8 Aerts et al. (18). In the case of a negative control qPCR, the hypothesis would be that these patients have
9 cleared the infection, thanks to anti-*Toxoplasma* immune recovery. For the two patients in our case, we
10 still decided to introduce prophylactic treatment, whereas Aerts et al. do not propose specific treatment
11 (18). Secondly, some patients can control TI with a prophylactic dosage treatment (80% of patients in
12 this study receiving prophylactic dosage treatment became qPCR-negative without a need for treatment
13 increase to non-prophylactic dosage), whereas others need non-prophylactic dosage treatment. The
14 introduction of a pre-emptive treatment at a prophylactic or intermediate dosage can be regarded as a
15 reasonable option when associated with close clinical and qPCR monitoring integrating parasitic load
16 quantification.

17 Most cases were diagnosed among donor negative/recipient positive alloHSCT, as already reported
18 (10,13,19,21,28,29), confirming that reactivation is the main explanation for *T. gondii* infection: this
19 raises the issue of whether or not to include the seronegative patients into the qPCR screening strategy
20 (10,13,19,21,28–30). In our cohort, four TI and one TD occurred in pre-alloHSCT seronegative patients,
21 i.e. a prevalence among seronegative recipients of 1%. One hypothesis for this finding is false-negative
22 serology, due to an impaired or waning immunity, knowing that transmission of infection via the graft
23 is also possible, although never demonstrated (10,19,28,29,31). When feasible, a negative pre-alloHSCT
24 serology should be controlled on a previous sample, dating from the hematological malignancy
25 diagnosis. To include or not seronegative patients in the screening is a cost-effectiveness issue that
26 should be balanced with local seroprevalence, available financial resources and the risk of missing
27 *Toxoplasma* disease, knowing that the seronegative population is growing (23).

1 The strength of our study is the large size of our cohort and the systematic screening of all alloHSCT
2 recipients over a 10-year period, using similar serological and molecular tools. However, the
3 retrospective nature of our study is a limit: sampling was not performed similarly in all patients, making
4 it difficult to interpret the kinetics of the parasitic load. Similarly, therapeutic attitudes were dependent
5 on physician decisions, in the absence of clear recommendations on the molecules and doses to be used.
6 Despite these limits, in cases of asymptomatic TI diagnosed before the start of prophylaxis, the
7 introduction of a pre-emptive treatment at a prophylactic or intermediate dosage could lead to *T. gondii*
8 control: this strategy could decrease the potential toxicity of P/Sa or high-dose TMP/SMX treatments.
9 When occurring in patients already receiving anti-*Toxoplasma* prophylaxis, one can also propose
10 continuing prophylaxis, without necessarily increasing treatment dosage or changing molecules, with
11 close clinical and qPCR monitoring.

12 In conclusion, in this large cohort of alloHSCT recipients with systematic *Toxoplasma gondii* qPCR
13 screening until D100, we report a 4.13% prevalence of toxoplasmosis, with a no attributable mortality.
14 It is important to start qPCR screening before engraftment, since most of our cases occurred before D30
15 and to continue until D100, then according to clinical suspicion. Optimal treatment dosage in
16 asymptomatic qPCR-positive patients remains to be established, both in cases of the patient receiving
17 prophylaxis or not. In any case, we advocate for a close monitoring of the parasitic load using qPCR to
18 adjust therapeutic attitudes.

19

1 **Acknowledgments**

2 The authors wish to thank all the technical staff of the laboratory for performing the biological tests, and
3 nurses who took care of the patients, as well as Ms. Sylvie Lengay for data extraction and Mr.
4 David Williams for manuscript editing.

5

6 **Author contributions:**

7 AX, AV, GS and SB designed the study protocol, conducted the search, extracting and analyzing data,
8 interpreted results, and wrote the manuscript. DM conducted the statistical analyses. SH, JM and SB
9 conducted and interpreted the qPCR tests. AX, AV, DM, MR, FSF, ND and RPL took care of patients.

10 All authors read and approved the manuscript before submission.

11

12 **Conflict of interest**

13 None.

14

1 **References**

- 2 1. Rauwolf KK, Floeth M, Kerl K, Schaumburg F, Groll AH. Toxoplasmosis after allogeneic
3 haematopoietic cell transplantation—disease burden and approaches to diagnosis, prevention
4 and management in adults and children. *Clin Microbiol Infect.* 2021 Mar;27(3):378–88.
- 5 2. Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J, et al. Guidelines for Preventing
6 Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global
7 Perspective. *Biol Blood Marrow Transplant.* 2009 Oct;15(10):1143–238.
- 8 3. on behalf of the Infectious Diseases Working Party of the German Society for Hematology and
9 Medical Oncology (AGIHO/DGHO) and the DAG-KBT (German Working Group for Blood and
10 Marrow Transplantation), Ullmann AJ, Schmidt-Hieber M, Bertz H, Heinz WJ, Kiehl M, et al.
11 Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and
12 prophylaxis strategy guidelines 2016. *Ann Hematol.* 2016 Sep;95(9):1435–55.
- 13 4. Martino R, Bretagne S, Einsele H, Maertens J, Ullmann AJ, Parody R, et al. Early Detection of
14 Toxoplasma Infection by Molecular Monitoring of *Toxoplasma gondii* in Peripheral Blood
15 Samples after Allogeneic Stem Cell Transplantation. *Clin Infect Dis.* 2005 Jan 1;40(1):67–78.
- 16 5. Lim Z, Baker B, Zuckermann M, Wade JJ, Ceesay M, Ho AYL, et al. Toxoplasmosis following
17 alemtuzumab based allogeneic haematopoietic stem cell transplantation. *J Infect.* 2007
18 Feb;54(2):e83–6.
- 19 6. Bretagne S, Costa JM, Foulet F, Jabot-Lestang L, Baud-Camus F, Cordonnier C. Prospective study
20 of toxoplasma reactivation by polymerase chain reaction in allogeneic stem-cell transplant
21 recipients: *T. gondii* PCR for SCT recipients. *Transpl Infect Dis.* 2000 Sep;2(3):127–32.
- 22 7. Robin C, Leclerc M, Angebault C, Redjoul R, Beckerich F, Cabanne L, et al. Toxoplasmosis as an
23 Early Complication of Allogeneic Hematopoietic Cell Transplantation. *Biol Blood Marrow*
24 *Transplant.* 2019 Dec;25(12):2510–3.
- 25 8. De Medeiros BC, De Medeiros CR, Werner B, Loddo G, Pasquini R, Bleggi-Torres LF.
26 Disseminated toxoplasmosis after bone marrow transplantation: report of 9 cases:
27 Disseminated toxoplasmosis after BMT. *Transpl Infect Dis.* 2001 Mar;3(1):24–8.
- 28 9. Mele A, Paterson P, Prentice H, Leoni P, Kibbler C. Toxoplasmosis in bone marrow
29 transplantation: a report of two cases and systematic review of the literature. *Bone Marrow*
30 *Transplant.* 2002 Apr 1;29(8):691–8.
- 31 10. Derouin F, Devergie A, Auber P, Gluckman E, Beauvais B, Garin YJF, et al. Toxoplasmosis in Bone
32 Marrow-Transplant Recipients: Report of Seven Cases and Review. *Clin Infect Dis.* 1992 Aug
33 1;15(2):267–70.
- 34 11. Matsuo Y, Takeishi S, Miyamoto T, Nonami A, Kikushige Y, Kunisaki Y, et al. Toxoplasmosis
35 encephalitis following severe graft-vs.-host disease after allogeneic hematopoietic stem cell
36 transplantation: 17 yr experience in Fukuoka BMT group: Toxoplasmosis encephalitis after allo-
37 HSCT. *Eur J Haematol.* 2007 Oct;79(4):317–21.
- 38 12. Redjoul R, Robin C, Foulet F, Leclerc M, Beckerich F, Cabanne L, et al. Pneumocystis jirovecii
39 pneumonia prophylaxis in allogeneic hematopoietic cell transplant recipients: can we always
40 follow the guidelines? *Bone Marrow Transplant.* 2019 Jul;54(7):1082–8.

- 1 13. Martino R, Maertens J, Bretagne S, Rovira M, Deconinck E, Ullmann AJ, et al. Toxoplasmosis
2 after Hematopoietic Stem Cell Transplantation. *Clin Infect Dis*. 2000 Nov 15;31(5):1188–94.
- 3 14. Menotti J, Garin YJF, Thulliez P, Sérugue MC, Stanislawiak J, Ribaud P, et al. Evaluation of a new
4 5'-nuclease real-time PCR assay targeting the *Toxoplasma gondii* AF146527 genomic repeat.
5 *Clin Microbiol Infect*. 2010 Apr;16(4):363–8.
- 6 15. Carreras E, Dufour C, Mohty M, Kröger N, editors. *The EBMT Handbook: Hematopoietic Stem
7 Cell Transplantation and Cellular Therapies* [Internet]. Cham: Springer International Publishing;
8 2019 [cited 2022 Sep 26]. Available from: <http://link.springer.com/10.1007/978-3-030-02278-5>
- 9 16. Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, et al. The MIQE Guidelines:
10 Minimum Information for Publication of Quantitative Real-Time PCR Experiments. *Clin Chem*.
11 2009 Apr 1;55(4):611–22.
- 12 17. Foot AB, Garin YJ, Ribaud P, Devergie A, Derouin F, Gluckman E. Prophylaxis of toxoplasmosis
13 infection with pyrimethamine/sulfadoxine (Fansidar) in bone marrow transplant recipients.
14 *Bone Marrow Transplant*. 1994 Aug;14(2):241–5.
- 15 18. Aerts R, Mercier T, Beckers M, Schoemans H, Lagrou K, Maertens J. Toxoplasmosis after
16 allogeneic haematopoietic cell transplantation: experience using a PCR-guided pre-emptive
17 approach. *Clin Microbiol Infect*. 2022 Mar;28(3):440–5.
- 18 19. Conrad A, Le Maréchal M, Dupont D, Ducastelle-Leprêtre S, Balsat M, Labussière-Wallet H, et al.
19 A matched case–control study of toxoplasmosis after allogeneic haematopoietic stem cell
20 transplantation: still a devastating complication. *Clin Microbiol Infect*. 2016 Jul;22(7):636–41.
- 21 20. Fricker-Hidalgo H, Bulabois C, Brenier-Pinchart M, Hamidfar R, Garban F, Brion J, et al. Diagnosis
22 of Toxoplasmosis after Allogeneic Stem Cell Transplantation: Results of DNA Detection and
23 Serological Techniques. *Clin Infect Dis*. 2009 Jan 15;48(2):e9–15.
- 24 21. Paccoud O, Guitard J, Labopin M, Surgers L, Malard F, Battipaglia G, et al. Features of
25 *Toxoplasma gondii* reactivation after allogeneic hematopoietic stem-cell transplantation in a
26 high seroprevalence setting. *Bone Marrow Transplant*. 2020 Jan;55(1):93–9.
- 27 22. Meers S, Lagrou K, Theunissen K, Dierickx D, Delforge M, Devos T, et al. Myeloablative
28 Conditioning Predisposes Patients for *Toxoplasma gondii* Reactivation after Allogeneic Stem
29 Cell Transplantation. *Clin Infect Dis*. 2010 Apr 15;50(8):1127–34.
- 30 23. Guigue N, Léon L, Hamane S, Gits-Muselli M, Le Strat Y, Alanio A, et al. Corrigendum:
31 Continuous Decline of *Toxoplasma gondii* Seroprevalence in Hospital: A 1997–2014
32 Longitudinal Study in Paris, France. *Front Microbiol*. 2018 Nov 27;9:2814.
- 33 24. Foroutan-Rad M, Majidani H, Dalvand S, Daryani A, Kooti W, Saki J, et al. Toxoplasmosis in
34 Blood Donors: A Systematic Review and Meta-Analysis. *Transfus Med Rev*. 2016 Jul;30(3):116–
35 22.
- 36 25. Reischl U, Bretagne S, Krüger D, Ernault P, Costa JM. Comparison of two DNA targets for the
37 diagnosis of Toxoplasmosis by real-time PCR using fluorescence resonance energy transfer
38 hybridization probes. *BMC Infect Dis*. 2003 Dec;3(1):7.

- 1 26. Isa F, Saito K, Huang YT, Schuetz A, Babady NE, Salvatore S, et al. Implementation of Molecular
2 Surveillance After a Cluster of Fatal Toxoplasmosis at 2 Neighboring Transplant Centers. *Clin*
3 *Infect Dis.* 2016 Aug 15;63(4):565–8.
- 4 27. Bretagne S, Costa JM, Kuentz M, Simon D, Vidaud M, Fortel I, et al. Late toxoplasmosis
5 evidenced by PCR in a marrow transplant recipient. *Bone Marrow Transplant.* 1995
6 May;15(5):809–11.
- 7 28. Chandrasekar P, Momin F, The Bone Marrow Transplant Team. Disseminated toxoplasmosis in
8 marrow recipients: a report of three cases and a review of the literature. *Bone Marrow*
9 *Transplant.* 1997 Apr 1;19(7):685–9.
- 10 29. Gajurel K, Dhakal R, Montoya JG. Toxoplasma prophylaxis in haematopoietic cell transplant
11 recipients: a review of the literature and recommendations. *Curr Opin Infect Dis.* 2015
12 Aug;28(4):283–92.
- 13 30. Štajner T, Vujić D, Srbljanović J, Bauman N, Zečević Ž, Simić M, et al. Risk of reactivated
14 toxoplasmosis in haematopoietic stem cell transplant recipients: a prospective cohort study in a
15 setting withholding prophylaxis. *Clin Microbiol Infect.* 2022 May;28(5):733.e1-733.e5.
- 16 31. Dupont D, Fricker-Hidalgo H, Brenier-Pinchart MP, Garnaud C, Wallon M, Pelloux H. Serology
17 for Toxoplasma in Immunocompromised Patients: Still Useful? *Trends Parasitol.* 2021
18 Mar;37(3):205–13.

19

20

1 **Table 1: Molecules and dosages used for *Toxoplasma* prophylaxis and treatment**

Dosage / treatment	Prophylactic	Non-prophylactic	
		Intermediate	High
TMP/SMX	400 mg/d or 800 mg/d given three days/week	800-1 600 mg/d	2 400-4 800 mg/d
P/So	1 500 mg/75 mg once weekly		
Atovaquone	750 mg bid		
P/Sa			P: 50-100 mg Sa: 4 000-6 000 mg/d

2

3 Abbreviations: d: day; mg: milligrams; P: pyrimethamine; Sa: sulfadiazine; So: sulfadoxine;

4 TMP/SMX: trimethoprim/sulfamethoxazole

5

1 **Table 2: Characteristics of the 52 *T. gondii* positive qPCR patients according to the time of qPCR-**
 2 **positivity and the presence or not of prophylaxis at the first qPCR-positive result**
 3

	Total	≤ D100, w/o prophylaxis	≤ D100 with prophylaxis	> D100
Number of episodes	52	30 (57.7)	14 (26.9)	8 (15.4)
Patients features, n (%)				
Male gender, n (%)	31 (59.6)	16 (53.3)	10 (71.4)	5 (62.5)
Median age at alloHSCT, yrs [IQR]	42 [28-52]	42 [25-52]	40 [30-52]	46 [36-51]
Underlying hematological condition				
Acute myeloid leukemia	21 (40.4)	10 (33.3)	6 (42.9)	5 (62.5)
Acute lymphoblastic leukemia	8 (15.4)	5 (16.7)	2 (14.3)	1 (12.5)
Myelodysplastic syndrome	4 (7.7)	3 (10)	1 (7.1)	0
Myeloproliferative neoplasm	9 (17.3)	8 (26.7)	1 (7.1)	0
Non-Hodgkin lymphoma	2 (3.8)	0	1 (7.1)	1 (12.5)
Hodgkin lymphoma	1 (1.9)	1 (3.3)	0	0
Sickle cell disease	3 (5.8)	2 (6.7)	1 (7.1)	0
Others*	4 (7.7)	1 (3.3)	2 (14.3)	1 (12.5)
D / R <i>T. gondii</i> IgG, n (%)				
D unknown / R negative	1 (1.9)	0	0	1 (12.5)
D positive / R positive	7 (13.5)	5 (16.7)	1 (7.1)	1 (12.5)
D negative / R positive	40 (76.9)	25 (83.3)	10 (71.4)	5 (62.5)
D positive / R negative	2 (3.8)	0	1 (7.1)	1 (12.5)
D negative / R negative	2 (3.8)	0	2 (14.3)	0
Positive <i>T. gondii</i> qPCR results				
Median number, n [IQR]	2 [1-4]	3 [2-4]	1.5 [1-4]	1.5 [1-2]
Median days from alloHSCT to first positive qPCR, [IQR]	26 [17-60]	19 [14-25]	48 [28-61]	202 [163-282]
D0 to D30, n (%)	30 (57.7)	25 (83.3)	5 (35.7)	N/A
D31 to D100, n (%)	14 (26.9)	5 (16.7)	9 (64.3)	N/A
Median days from first positive to first negative qPCR**, [IQR]	11 [7-17]	12 [7-15.5]	11 [6-18]	11 [7-18]
<i>T. gondii</i> infection, n (%)	45 (86.5)	28 (93.3)	12 (85.7)	5 (62.5)

<i>T. gondii</i> disease, n (%)	7 (13.5)	2 (6.7)	2 (14.3)	3 (37.5)
Toxoplasmosis-attributable death, n (%)	0	N/A	N/A	N/A
Death-contributing TI or TD, n (%)	3 (5.8)	2 (6.7)	0	1 (12.5)

1

2 Abbreviations; alloHSCT: allogeneic hematopoietic stem cell transplantation; D: donor; IQR:

3 interquartile range; N/A: not applicable; qPCR: quantitative polymerase chain reaction; R: recipient; TI:

4 *Toxoplasma* infection; TD: *Toxoplasma* disease; w/o: without; yrs: years.

5 * Aplastic anemia (n= 3), primary immune deficiency (n= 1)

6 ** Three missing data

7

1 **Supplementary Table 1: Additional characteristics of the 52 *T. gondii* positive qPCR patients**
 2 **according to the time of qPCR-positivity and the presence or not of prophylaxis at the first qPCR-**
 3 **positive result**

4

	Total	≤ D100, w/o prophylaxis	≤ D100 with prophylaxis	W/o vs. with prophylaxis, Adjusted p-value (Bonferroni-Dunn)	>D100
Number of episodes	52	30 (57.7)	14 (26.9)		8
Patients features, n (%)					
Donor type				0.63	
Matched related	11 (21.2)	5 (16.7)	4 (28.6)		2 (25.0)
Matched unrelated	19 (36.5)	12 (40.0)	3 (21.4)		4 (50.0)
Mismatched unrelated	18 (34.6)	11 (36.7)	6 (42.9)		1 (12.5)
Haplo-identical	3 (5.8)	2 (6.7)	1 (7.1)		0
Unknown	1 (1.9)	0	0		1 (12.5)
Conditioning regimen				0.61	
Myelo-ablative	23 (44.2)	14 (46.7)	7 (50.0)		2 (25.0)
Reduced-intensity	26 (50.0)	14 (46.7)	7 (50.0)		5 (62.5)
Sequential	3 (5.8)	2 (6.7)	0		1 (12.5)
Including anti-thymoglobulin / alemtuzumab	39 (75.0)	26 (86.7)	8 (57.1)		5 (62.5)
Stem cell source				0.24	
Peripheral blood	40 (76.9)	22 (73.3)	10 (71.4)		8 (100)
Bone marrow	7 (13.5)	6 (20)	1 (7.1)		0
Cord blood	5 (9.6)	2 (6.7)	3 (21.4)		0
Characteristics at first positive qPCR					
Median age (yrs) [IQR]	42 [28-52]	42 [25-52]	40 [30-52]	1	46 [37-52]
Relapse after alloHSCT	8 (15.4)	4 (13.3)	3 (21.4)	0.66	1 (12.5)
Median time from alloHSCT to relapse (days)	177 [99-381]	262 [140-472]	199 [149-307]	1	92
TI/TD after relapse	1 (1.9)	0	0	NA	1 (12.5)
Died after alloHSCT	22 (42.3)	10 (33.3)	9 (64.3)	0.1	3 (37.5)
Median time from alloHSCT to death (days)	155 [77-253]	66 [50-173]	182 [139-234]	1	259 [204-445]
Cause of death				0.45	
GVHD	10 (19.2)	5 (16.7)	5 (35.7)		2 (25.0)
GVHD and TI	2 (3.8)	2 (6.7)	0		0
Relapse	3 (5.8)	1 (3.3)	2 (14.3)		0
Relapse and TD (CNS)	1 (1.9)	0	0		1 (12.5)

Other infection	6 (11.5)	4 (13.3)	2 (14.3)		0
Chemotherapy	1 (1.9)	0	0	NA	1 (12.5)
Immunosuppressive treatment	50 (96.2)	28 (93.3)	14 (100)	1	7 (87.5)
Steroids	23 (44.2)	10 (33.3)	6 (42.9)	0.73	7 (87.5)
Calcineurin inhibitor	37 (71.1)	22 (73.3)	10 (71.4)	1	4 (50.0)
Mycophenolate mofetil	13 (25)	13 (43.3)	0	0.0034	2 (25.0)
Ruxolitinib	2 (3.8)	0	2 (14.3)	0.09	2 (25.0)
Anti-TNF	2 (3.8)	0	1 (7.1)	0.31	1 (12.5)
Everolimus	3 (5.8)	0	2 (14.3)	0.09	1 (12.5)
≥ 2 immunosuppressants	28 (53.8)	17 (56.7)	5 (35.7)	0.33	6 (75.0)
Steroids + ≥ 1 immunosuppressant	17 (32.7)	7 (28.3)	5 (35.7)	0.47	7 (87.5)
Median gamma globulin level (g/L)	5.05 [3.1-7.1]	6 [4.7-6.9]	3.5 [2.5-8.6]	1	3 [1.8-4.8]
Median white blood cells (G/L)	2.9 [0.9-5.9]	1.2 [0.1-3.7]	4.9 [2.3-7.2]	1	5.3 [3-6.6]
Median peripheral blood lymphocytes (G/L)	0.2 [0-0.5]	0.1 [0-0.25]	0.4 [0.1-1.1]	0.024	0.75 [0.4-1.1]
<i>T. gondii</i> infection	45 (86.5)	28 (93.3)	12 (85.7)	0.51	5 (62.5)
<i>T. gondii</i> disease (CNS)	7 (13.5)	2 (6.7)	2 (14.3)		3 (37.5)
Neurological symptoms	3 (5.8)				1 (12.5)
Symptoms at first positive qPCR	11 (20.8)	6 (20.0)	1 (7.1)		4 (50.0)
Fever	9 (17.3)	4 (13.3)	1 (7.1)		4 (50.0)
Radiologic work-up not performed (no symptoms)	20 (38.5)	10 (33.3)	8 (57.1)		2 (25.0)
Radiologic work-up performed	33 (63.5)	20 (66.7)	6 (42.9)		6 (75.0)
CNS MRI	22 (42.3)	13 (43.3)	5 (35.7)		4 (50.0)
including abnormal CNS MRI findings	7 (13.5)	2 (6.7)	2 (14.3)		3 (37.5)
CNS TDM	7 (13.5)	5 (16.7)	1 (7.1)		1 (12.5)
including abnormal CNS TDM findings	0	0	0		0
Thoraco-abdominal TDM	22 (42.3)	15 (50.0)	5 (35.7)		2 (12.0)
including toxoplasmosis-related abnormal findings	0	0	0		0
Ophthalmological examination	10 (19.2)	6 (20.0)	2 (14.3)		2 (25.0)
including toxoplasmosis-related abnormal findings	0	0	0		0

1 Abbreviations: alloHSCT: allogeneic hematopoietic stem cell transplantation; CNS: central nervous
2 system; D: donor; GVHD: graft-versus-host disease; IQR: interquartile range; MRI: magnetic resonance
3 imaging; qPCR: quantitative polymerase chain reaction; R: recipient; TD: *Toxoplasma* disease; TDM:
4 tomodesitometry; TI: *Toxoplasma* infection; TNF: tumor-necrosis factor; vs: versus; w/o: without; yrs:
5 years
6
7

1 **Figure legends**

2

3 **Figure 1: Positive *Toxoplasma* qPCR before D100 in patients without anti-*Toxoplasma***

4 **prophylaxis** **Figure 2: Positive *Toxoplasma* qPCR before D100 in patients receiving anti-**

5 ***Toxoplasma* prophylaxis**

6

7 **Figure 3: Positive *Toxoplasma* qPCR after D100**

8

9 **Figure 4: Evolution of *Toxoplasma gondii* DNA load by qPCR on blood sample in 24 patients**

10 **without anti-*Toxoplasma* prophylaxis, diagnosed before D100 with TI (n= 22) or TD (n= 2).**

11 **Figure 4a: 14 patients received pre-emptive treatment at prophylactic dosage (prophylactic**

12 **TMP/SMX, n= 13 and atovaquone, n= 1 (P#11))**

13 **Figure 4b: Four patients received pre-emptive treatment at non-prophylactic dosage with**

14 **intermediate dosage TMP/SMX (800-1600mg/day). P#4 died of GVHD with persistently positive**

15 **qPCR**

16 **Figure 4c: Six patients received pre-emptive treatment at non-prophylactic dosage with high**

17 **dosage TMP/SMX (n= 2, P#13 and 14) or P/Sa (n= 4). P#14 died of GVHD with persistently**

18 **positive qPCR.**

19

1 **Figure 1**

2 Abbreviations: AE: adverse event; ATO: atovaquone; CNS: central nervous system; CR: complete
3 remission; d: day; IV: intra-venous; neg: negative; P: pyrimethamine; pos: positive; Sa: sulfadiazine;
4 So: sulfadoxine; TD: *Toxoplasma* disease; TMP/SMX: trimethoprim/sulfamethoxazole; ttt: treatment.
5 Treatment length before PCR-negativity is indicated in brackets.

6

7 **Figure 2**

8 Abbreviations: AE: adverse event; ATO: atovaquone; CNS: central nervous system; CR: complete
9 remission; d: day; IV: intra-venous; neg: negative; P: pyrimethamine; pos: positive; Sa: sulfadiazine;
10 So: sulfadoxine; TD: *Toxoplasma* disease; TMP/SMX: trimethoprim/sulfamethoxazole; ttt: treatment.
11 Treatment length before PCR-negativity is indicated in brackets.

12

13 **Figure 3**

14 Abbreviations: ALL: acute lymphoblastic leukemia; CR: complete remission; CNS: central nervous
15 system; d: day; GVHD: graft-versus-host-disease; P: pyrimethamine; Sa: sulfadiazine; So:
16 sulfadoxine; TMP/SMX: trimethoprim/sulfamethoxazole; Treatment length before PCR-negativity is
17 indicated in brackets.

18 *TMP/SMX changed to P/So in one patient as P/So commercialization stopped at that time.

19

20 **Figure 4:**


21 From a starting sample with 45 Cq value corresponding to no detectable circulating DNA, patients had
22 a decrease of Cq values (i.e. an increase of blood parasite load) until the day of pre-emptive treatment
23 (D0), followed by an increase of Cq values (i.e. the decrease of blood parasite load) until negation or a
24 persistent parasite load in two patients (P#29 and P#14)

25

26

27

Toxoplasma qPCR-positive before D100 without prophylaxis (n= 30)





Toxoplasma qPCR-positive before D100 while receiving prophylaxis (n= 14)

INITIAL
PROPHYLAXIS


MODIFICATIONS
DRUG/POSOLGY

OUTCOME






4a




- P#15
- P#12
- △ P#18
- P#10
- P#16
- ⊙ P#20
- ▣ P#21
- ▵ P#23
- ▾ P#25
- ◇ P#26
- * P#9
- ★ P#27
- P#11
- ✱ P#30

4b



4c



○ P#1 □ P#6 * P#5 × P#13 ● P#3 ● P#14